Begin main content

Call for Patient Input: ocrelizumab

Published on: April 18, 2017
Result type: News

CADTH has received the following drug submission(s) and/or notice(s) of pending submission(s). If you are interested in providing patient input, please click on “Submit.” For information about the patient input process or for additional instructions, please see the Patient Input page of our website.

ocrelizumab

Brand name Generic name Manufacturer Indication(s)
TBC ocrelizumab Hoffman-La Roche Limited multiple sclerosis, relapsing
Project Number Call for patient input Patient input deadline Submit patient input
TBC 2017-04-18 2017-06-07 Submit